The estimated Net Worth of Venture Fund Iii, L.P.River... is at least $1.01 million dollars as of 14 October 2020. Venture River owns over 250,000 units of Spruce Biosciences stock worth over $1,009,692 and over the last 4 years Venture sold SPRB stock worth over $0.
Venture has made over 1 trades of the Spruce Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture bought 250,000 units of SPRB stock worth $3,750,000 on 14 October 2020.
The largest trade Venture's ever made was buying 250,000 units of Spruce Biosciences stock on 14 October 2020 worth over $3,750,000. On average, Venture trades about 250,000 units every 0 days since 2020. As of 14 October 2020 Venture still owns at least 2,148,281 units of Spruce Biosciences stock.
You can see the complete history of Venture River stock trades at the bottom of the page.
Over the last 4 years, insiders at Spruce Biosciences have traded over $10,017,426 worth of Spruce Biosciences stock and bought 4,788,400 units worth $38,247,728 . The most active insiders traders include Holdings A/S Novo, Bali Muralidhar et Niall O'donnell. On average, Spruce Biosciences executives and independent directors trade stock every 57 days with the average trade being worth of $210,541. The most recent stock trade was executed by Holdings A/S Novo on 21 March 2024, trading 465,021 units of SPRB stock currently worth $348,766.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH). It offers tildacerfont, which is in Phase II clinical trial for children with classic CAH; and for females with polycystic ovary syndrome. In addition, it is involved in developing CAHmelia-203 which is in Phase 2b clinical trial for adult patients with classic CAH with poor disease control; and CAHmelia-204, which is in second Phase 2b clinical trial in adult patients with classic CAH with good disease control. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Spruce Biosciences executives and other stock owners filed with the SEC include: